title: [Preliminary mechanism of paclitaxel enhanced radiation sensitivity for nasopharyngeal carcinoma cells].
abstract: OBJECTIVE
  To study the radiation-sensitizing function and preliminary mechanism of paclitaxel in radiation-resistant nasopharyngeal carcinoma cells.
  
  
  METHODS
  X-ray dose fractionated irradiation technology to build radiation-resistant subline of nasopharyngeal carcinoma; CNE-2S1 was treated with paclitaxel alone or combined with radiation therapy, while control group treated with radiation therapy; cell colony formation assay was used to observe sensitizing effect of paclitaxel on radiotherapy; flow cytometry analysis was used to analyze cell cycle distribution and apoptosis ratio of different treatment groups; immunoblotting was used to analyze SHP-1 expression levels of different treatment groups.
  
  
  RESULTS
  Nasopharyngeal carcinoma cells resistant to radiation was successfully established; cell colony formation assay showed that paclitaxel has obvious sensitizing effect on radiotherapy; FACS results showed that: CNE-2S1 treated by paclitaxel were arrested in G2M phase; paclitaxel and radiotherapy treatments significantly improved the CNE-2S1 apoptosis ratio; Western blot results showed that paclitaxel and combined radiotherapy can reduce the CNE-2S1 cells SHP-1 expression levels.
  
  
  CONCLUSIONS
  Paclitaxel enhanced radiation therapy for nasopharyngeal carcinoma cells resistant to radiation, and SHP-1 may be involved in this progress.
authors.forename: Xi
authors.initials: X
authors.lastname: Chen
authors.forename: Zhenwei
authors.initials: Z
authors.lastname: Zou
authors.forename: Xiaofen
authors.initials: X
authors.lastname: Pan
authors.forename: Jingjing
authors.initials: J
authors.lastname: Mou
authors.forename: Gang
authors.initials: G
authors.lastname: Peng
mesh_terms: D017209:Apoptosis / Q000187:drug effects; D002277:Carcinoma; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D006801:Humans; D000077274:Nasopharyngeal Carcinoma; D009303:Nasopharyngeal Neoplasms / Q000473:pathology*; D017239:Paclitaxel / Q000494:pharmacology*; D053824:Protein Tyrosine Phosphatase, Non-Receptor Type 6 / Q000378:metabolism; D011836:Radiation Tolerance / Q000187:drug effects*
chemical_list: C509249:PTPN6 protein, human; D053824:Protein Tyrosine Phosphatase, Non-Receptor Type 6; D017239:Paclitaxel